These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 10791375)

  • 1. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
    International Collaboration on HIV and Cancer
    J Natl Cancer Inst; 2000 Nov; 92(22):1823-30. PubMed ID: 11078759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1158-9. PubMed ID: 10791383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study.
    van Benthem BH; Veugelers PJ; Cornelisse PG; Strathdee SA; Kaldor JM; Shafer KA; Coutinho RA; van Griensven GJ
    AIDS; 1998 Jun; 12(9):1039-45. PubMed ID: 9662201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
    J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters.
    Biggar RJ
    AIDS; 1990 Nov; 4(11):1059-66. PubMed ID: 2282177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with progression to AIDS and mortality in a cohort of HIV-infected patients with hemophilia followed up since seroconversion.
    Santagostino E; Gringeri A; Cultraro D; Tradati F; Siracusano L; Marinoni A; Mannucci PM
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):371-80. PubMed ID: 7580830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
    O'Brien TR; Blattner WA; Waters D; Eyster E; Hilgartner MW; Cohen AR; Luban N; Hatzakis A; Aledort LM; Rosenberg PS; Miley WJ; Kroner BL; Goedert JJ
    JAMA; 1996 Jul; 276(2):105-10. PubMed ID: 8656501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.
    Touloumi G; Karafoulidou A; Gialeraki A; Katsarou O; Milona I; Kapsimali V; Mandalaki T; Hatzakis A
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):89-97. PubMed ID: 9732075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 disease progression and AIDS-defining disorders in rural Uganda.
    Morgan D; Maude GH; Malamba SS; Okongo MJ; Wagner HU; Mulder DW; Whitworth JA
    Lancet; 1997 Jul; 350(9073):245-50. PubMed ID: 9242801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
    Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
    Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
    d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
    Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
    Clements M; Law M; Pedersen C; Kaldor J;
    HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up.
    Glynn JR; Sonnenberg P; Nelson G; Bester A; Shearer S; Murray J
    AIDS; 2007 Mar; 21(5):625-32. PubMed ID: 17314525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion associated AIDS in Mexico. Clinical spectrum, conditional latency distribution, and survival.
    Volkow P; Ponce de León S; Calva J; Ruiz-Palacios G; Mohar A
    Rev Invest Clin; 1993; 45(2):133-8. PubMed ID: 8337540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.